The effect of short-term immunotherapy with molecular standardized grass and rye allergens on eosinophil cationic protein and tryptase in nasal secretions

Klimek, Ludger; Wolf, Hendrik; Mewes, T.; Dormann, D; Reske‐Kunz, Angelika B.; Schnitker, J; Mann, Wolf J.

doi:10.1016/s0091-6749(99)70524-5

Cited by 39 publications

(41 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The efficacy of subcutaneous immunotherapy (SCIT) has been demonstrated in a number of controlled clinical trials [3,4,5,6]. Other studies have investigated short-term hyposensitization schedules designed to reduce the titration phase and increase patient compliance [7,8,9]. Cluster regimens are an interesting option in this respect as they offer a shorter initial build-up phase with a lower rate of adverse events (AEs).…”

Section: Introductionmentioning

confidence: 99%

Safety of Two Cluster Schedules for Subcutaneous Immunotherapy in Allergic Rhinitis or Asthma Patients Sensitized to Inhalant Allergens

Pfaar

Klimek

Fischer

et al. 2009

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Subcutaneous immunotherapy (SCIT) usually requires a long titration phase, which can be associated with various adverse events (AEs). Objectives: It was the aim of this study to determine the safety of 2 cluster regimens for SCIT in patients with allergic rhinitis, with or without mild or moderate allergic asthma, who were sensitized to grass and/or tree pollen, or house dust mites (HDM). Patients and Methods: Adult patients were included in a European, open-label, prospective trial. Pollen-allergic patients received grass pollen, grass and olive pollen, or hazel, alder and birch pollen according to a 3-week titration cluster. HDM-allergic patients received HDM extract according to a 2-week titration cluster. The safety of the titration phase was assessed in terms of local and systemic AEs. Results: The safety analysis included 157 patients: 110 received pollen and 47 HDM extract. During the cluster titration, 248 AE episodes were reported in the pollen group and 113 in the HDM group; these were mainly local reactions. Around one third of patients (30.9% pollen and 38.3% HDM) did not experience any AE. In most cases (67.1% of pollen and 71.1% of HDM patients), AEs did not lead to a change in titration schedule. No anaphylactic reaction or other serious life-threatening systemic AEs were reported. Only 2 patients in the HDM group discontinued treatment because of AEs. Conclusions: Rapid cluster titration was well tolerated in adults with allergic rhinitis, with or without mild to moderate allergic asthma, due to pollen or HDM. This short-titration, high-dose cluster regime may allow better patient compliance and cost savings.

show abstract

Section: Introductionmentioning

confidence: 99%

Safety of Two Cluster Schedules for Subcutaneous Immunotherapy in Allergic Rhinitis or Asthma Patients Sensitized to Inhalant Allergens

Pfaar

Klimek

Fischer

et al. 2009

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…This initial immunotherapy, called rush immunotherapy, has also been previously applied to other allergens, such as mites and pollens [2, 3], but the potential adverse effects that may occur in a less urgent situation than hymenoptera venom allergy has not allowed this method to proceed beyond the stage of clinical trials [4]. Some allergists use a cluster technique, midway between the ‘classical’ dose progression and ‘rush’ methods, which achieves maintenance treatment in 2 or 3 weeks, at a rate of several injections per day [5, 6]. However, the benefit-risk ratio of this method is still a subject of debate [7].…”

Section: Introductionmentioning

confidence: 99%

Safety and Efficacy of <i>Juniperus ashei</i> Sublingual-Swallow Ultra-Rush Pollen Immunotherapy in Cypress Rhinoconjunctivitis

Vervloët

Birnbaum

Laurent³

et al. 2006

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: The safety and efficacy of high-dose sublingual-swallow immunotherapy (SLIT) has been established in pollen rhinoconjunctivitis. This treatment has now been evaluated using an ultra-rush incremental dose regimen with a Juniperus ashei allergen extract in patients allergic to Cupressus sempervirens and Cupressus arizonica. Methods: Patients received either placebo or SLIT. Evaluation of safety was based on the frequency of adverse events during the incremental dose period (half a day) and during maintenance therapy (4 months). Evaluation of efficacy was based on symptom and medication scores at the pollen peak. Results: Seventy of the 76 patients included completed the study. There were no drop-outs during the rush procedure. One patient in the active group dropped out during the maintenance therapy due to adverse events: gastric pain and vomiting. There was also 1 drop-out in the placebo group due to pregnancy. Adverse events were infrequent, local and mild. Symptom scores for rhinitis and conjunctivitis were not statistically different between groups, but there was a marked and significant (p < 0.03) decrease of the medication score (about 50%) and nasal steroid consumption (about 75%) in the active treatment group. An increase from baseline of serum IgE and IgG4 J. ashei-specific antibodies was only observed in actively treated patients (p < 0.04 and p < 0.01, respectively). Conclusions: The tolerability and safety of high-dose ultra-rush SLIT were comparable to those reported in previous SLIT studies. SLIT with J. ashei extract, due to its high Jun a 1 content, significantly reduced nasal steroid consumption in patients allergic to European cypress.

show abstract

“…Ayrıca konvansiyonel IT tedavisinin uzun zaman alması nedeniyle her hasta için düşünülememektedir. Bu tür hastalar için uygulanan kısa süreli IT'nin, yeterli doz verilmesine bağlı olarak belirgin klinik etkinin gözlenmesine ilave olarak cilt testi duyarlı-lığında ve nazal sekresyonda inflamasyon belirteci olan eozinofil katyonik protein ve triptaz düzeylerinde azalma, serum spesifik IgG4 düzeyinde ise artışa neden olduğu çalışmalarca gösterilmiştir (8,9).…”

Section: Introductionunclassified

Evaluation of Preseasonal Immunotherapy in Patients with Seasonal Allergic Rhinitis

Tepetam¹,

Ferhan²

2014

J Chest Dis Crit Care

View full text Add to dashboard Cite

The aim of the present study was to evaluate clinical and laboratory efficacy of short term preseasonal immunotherapy by comparing immunotherapy (IT) and medical treatment administered to patients diagnosed with seasonal allergic rhinitis (AR). Patients were randomized into two groups: ie those who use preseasonal immunotherapy and drugs according to their need (IT group:12 patients ) Mevsimsel Alerjik Rinitli Hastalarda Mevsim Öncesi İmmünoterapi Etkinliğinin Değerlendirilmesi ÖZET Çalışmamızda, mevsimsel allerjik rinit (AR) tanısı koyduğumuz hastalara uygulanan mevsim öncesi immünoterapi (IT) ile medikal tedavi stratejilerini karşılaştırarak, mevsim öncesi kısa süreli immünoterapinin klinik ve laboratuvar etkinliğini değerlendirmeyi amaçladık. Hastalar mevsim öncesi IT tedavisi ile polen sezonunda ihtiyaca göre ilaç kullananlar (IT grup:12 hasta)

show abstract

The effect of short-term immunotherapy with molecular standardized grass and rye allergens on eosinophil cationic protein and tryptase in nasal secretions

Cited by 39 publications

References 39 publications

Safety of Two Cluster Schedules for Subcutaneous Immunotherapy in Allergic Rhinitis or Asthma Patients Sensitized to Inhalant Allergens

Safety of Two Cluster Schedules for Subcutaneous Immunotherapy in Allergic Rhinitis or Asthma Patients Sensitized to Inhalant Allergens

Safety and Efficacy of <i>Juniperus ashei</i> Sublingual-Swallow Ultra-Rush Pollen Immunotherapy in Cypress Rhinoconjunctivitis

Evaluation of Preseasonal Immunotherapy in Patients with Seasonal Allergic Rhinitis

Contact Info

Product

Resources

About